🔗 Share this article

While the US proceeds with sweeping revisions to its vaccine guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on COVID-19 shots during the global health crisis and has focused upon alleged deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders planned to reveal sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of alignment with a large portion of the world with little proof for improved outcomes. The planned update has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a strengthened alliance between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

The appointee has no apparent track record in pharmaceutical research, oversight or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She is not an expert in drug approvals.”

Previous commissioners of CBER would “understand regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran CBER have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock pointed out.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division clears a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and every single one need to be supervised,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership component to the job, which oversees in excess of 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” the former official added.

Official Statement and Contentious Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among regulatory chiefs on vaccines, a press secretary said that the “concerns stem from flawed premises”.

“This background matches the duties of her position,” the official stated, pointing to the months Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a disputed expedited therapy clearance system that reportedly worried her preceding directors. “How are these drugs being chosen for this expedited pathway? Who is making the calls?” Howard said. “There is a lot of secrecy happening at the agency right now.”

In general, he said, “the agency seems to be moving towards less stringent regulations of pharmaceuticals, with the exception of shots.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard have noted. She published a research paper using unverified crowd-sourced reports to estimate the incidence of heart inflammation following Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are riskier than they are.

Included in her “wish list” for the incoming administration featured revising guidelines for recently developed shots and halting “non-essential” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring teenage boys from receiving Covid vaccinations.

“She’s an complete ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the science in a highly deceptive, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|